These ADCs also use a proprietary payload system, based on a kinesin spindle protein inhibitor (KSPi). KSP is essential for mitosis, so when administered systemically, small-molecule KSPis are ...

POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second ...

We are on track to nominate a development candidate for our Kinesin program by mid-year ... oral, potent CHK1 inhibitor designed to target replication stress in oncogene-amplified cancers ...

Novel Kinesin program targeting ecDNA segregation ... directed therapeutic candidate (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 ...